Key result
Introduction of a pentavalent rotavirus vaccine was associated with an 87% reduction in community-acquired rotavirus gastroenteritis cases compared to the 2005-2006 season.
Why the study?
Does the introduction of a pentavalent rotavirus vaccine reduce cases of rotavirus gastroenteritis in children?
Observational
No
Does the introduction of a pentavalent rotavirus vaccine reduce cases of rotavirus gastroenteritis in children?
Answers are grounded in this paper and cite their sources.
The introduction of the pentavalent rotavirus vaccine was associated with an 87% reduction in community-acquired rotavirus gastroenteritis cases at a major pediatric hospital.
A pentavalent rotavirus vaccine for infants became available in the United States in February 2006. By 2007, vaccination rates nationwide were estimated to be approximately 50%. We studied the effectiveness of the vaccine in a real-world setting outside of a clinical trial. All children presenting to The Children's Hospital of Philadelphia with acute gastroenteritis have been monitored for the presence of rotavirus antigen in the stool by enzyme-linked immunosorbent assay (ELISA [followed by genotyping if ELISA positive]) since the 1994-1995 epidemic season, presenting a unique opportunity to assess the impact of the recently introduced vaccine. The annual number of community-acquired cases over the preceding 13 years had approached or exceeded 100, with 271 cases in 2005 to 2006 and 167 cases in 2006 to 2007. In the 2007-2008 season, only 36 community-acquired cases were identified, representing an 87% reduction from the same period in 2005 to 2006. G3 was the predominant serotype, accounting for 15 community cases (42%). Our study is limited by its observational design using historical comparisons. Nonetheless, the abrupt decline in rotavirus gastroenteritis cases during the 2007-2008 season likely resulted from vaccination. Because protection rates appeared to have exceeded vaccination rates, herd immunity may have contributed to some degree to the effectiveness of the vaccine.
No takes yet. Share an insight, caveat, or question.
Clark et al. (2009) conducted an observational in Rotavirus gastroenteritis. Pentavalent rotavirus vaccine vs. Historical pre-vaccine period (2005-2006) was evaluated on Community-acquired cases of rotavirus gastroenteritis (87% reduction). Introduction of a pentavalent rotavirus vaccine was associated with an 87% reduction in community-acquired rotavirus gastroenteritis cases compared to the 2005-2006 season.
Synapse has enriched 10 related papers. Consider them for comparative context: